A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Clinical Activity of ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Leigh disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors AADi
- 07 Dec 2019 Planned primary completion date changed from 31 Mar 2021 to 31 Dec 2021.
- 07 Dec 2019 Planned initiation date changed from 1 Sep 2019 to 1 Mar 2020.
- 23 Jul 2019 Planned initiation date changed from 1 Apr 2019 to 1 Sep 2019.